Yaprak Uckunkaya Esirgen

Leading the global strategy and pre-launch preparations of FABHALTA (iptacopan) in IgAN

Led the successful launch of FABHALTA (iptacopan) in PNH, approved in 44 countries, launched in 8, and exceeded expectations by being 123% above target

Led the US strategy of Kisqali early breast cancer launch

Led the global strategy and pre-launch preparations of FABHALTA (iptacopan) in PNH

Successfully launched Adakveo in 10 countries.

Led a marketing team of 7 product managers and a commercial portfolio of $100 million.
Launched Cosentyx with the best world-wide patient share uptake across 3 indications - PsO (15.3%), AS (9.5%) and PsA (19.4%) in 2018.
Outperformed the competition with Cosentyx and became the leader in PsO (27%) and PsA (23%) indications in 2020.
Maximized the potential of Ilaris, Xolair, Certican & Myfortic through strategic partnerships and LCM initiatives.
IHD Franchise grew by 96% in two years; with a total pharma sales contribution of 35%.

Successfully launched Entresto in private market – first ever in Novartis Turkey
Successfully designed and implemented an integrated hearth failure awareness campaign consisting of a website, Facebook page, radio program, cookbook, music video in collaboration with Turkish Society of Cardiology. Reached a total coverage of 70 million people via printed media, TV, and digital media.
Completed 3 months rotation in Thailand Entresto team; designed and implemented a patient activation campaign including a website, Facebook page, Youtube channel and a short movie. Reached total coverage of 10 million people.
Selected as a member of APMA Entresto Council – a regional team responsible for supporting Entresto launches across APMA.

Led pre-launch efforts of Entresto.
Built a competitive commercial strategy leading to growth of Diovan and Co-Diovan.

Leading marketing strategy and tactics for SWA parameters

Responsible for marketing strategy and tactics for SWA parameters

Responsible for marketing activities and tactics for spark plugs.